Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner

Am J Cardiol. 2004 Apr 15;93(8):1046-50. doi: 10.1016/j.amjcard.2004.01.014.


To test the hypothesis that variations in the multidrug resistance-1 gene influence the response to statin treatment, 2 prevalent polymorphisms (G2677T/A and C3435T) were examined in 344 hypercholesterolemic patients treated with atorvastatin (10 mg). The C3435T polymorphism was significantly and independently associated with a smaller reduction in low-density lipoprotein cholesterol and with a larger increase in high-density lipoprotein cholesterol, relative to variant allele carriers, in a gender-specific manner. Also, haplotype determination combined with these polymorphisms identified a subgroup that showed a striking response to treatment, which was not defined by a single polymorphism.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anticholesteremic Agents / pharmacology*
  • Anticholesteremic Agents / therapeutic use
  • Atorvastatin
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Female
  • Genes, MDR / genetics*
  • Heptanoic Acids / pharmacology*
  • Heptanoic Acids / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic
  • Pyrroles / pharmacology*
  • Pyrroles / therapeutic use
  • Sex Factors


  • Anticholesteremic Agents
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Heptanoic Acids
  • Pyrroles
  • Atorvastatin